Sandoz has signed a Memorandum of Understanding to build a new biologics production plant in Lendava, Slovenia. The Sandoz investment is expected to be at least $400 million, supporting the company’s ambition to drive the future growth of its global biosimilars portfolio. This represents one of the largest-ever international private-sector investments in Slovenia. Source: Drug Store News 14/3/2023